STING1 and neoplasm: The dimeric amidobenzimidazoles (diABZIs) are non-CDN STING agonists identified through in silico studies, which showed the ability to induce IFN-β, α-chemokine CXCL1 and IL-6 transcription, and anti-tumor activity [131].